We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Take a look at our previous reports:

Annual Report

2019

View Report

Q1 Report

2020

View Report

H1 Report

2020

View Report

Q3 Report

2020

View Report
English | Dutch
Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2020

  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos group
    • Letter from the management
    • COVID-19 impact
    • At a glance
    • Strategy
    • Going concern statement
    • Risk management and internal control
    • The Galapagos share
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • Our pipeline and drug discovery engine
    • Versatile target discovery platform
    • Our inflammation franchise
      • Filgotinib in RA
      • Filgotinib in IBD
      • Other indications with filgotinib
      • Our Toledo program
      • Our TYK2 program with GLPG3667
      • Our JAK1/TYK2 program with GLPG3121
      • Inlicensing to further strengthen the inflammation franchise
      • GLPG1972 in OA
    • Our fibrosis portfolio
      • About IPF
      • Our IPF trials
      • Our fibrosis collaborations
    • Other pipeline
  • Risk factors
    • Commercialization
    • Product development and regulatory approval
    • Financial position and need for additional capital
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • CSR report
    • Our commitment
    • Improving people’s lives
    • Our employees
    • Conducting business ethically
    • Environment, health, and safety
    • CSR at Galapagos – Summary
  • Corporate governance
    • Policies
    • Supervisory board
    • Committees
    • Management board
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Introduction
        • Remuneration policy
        • Peer group
      • Supervisory board
        • Compensation structure
        • Cash remuneration
        • Equity
      • Management board
        • Compensation structure
        • Criteria and methods to evaluate performance
        • Total remuneration
      • Equity components of the remuneration
        • Subscription rights
        • RSUs awarded to management board
      • 5-year evolution
      • Pay-ratio
      • Minimum share ownership
      • Provisions for severance
        • Provisions for severance
        • Severance payments
      • Claw-back right
      • Deviations from the remuneration policy
    • Conflict of interests and related parties
    • Code of Business Conduct and Ethics
    • Statement by the supervisory board
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income/loss (-)
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Summary of significant transaction
        • 3. Significant accounting policies
        • 4. Critical accounting judgments and key sources of estimation uncertainty
        • 5. Segment information
        • 6. Total revenues and other income
        • 7. Operating costs
        • 8. Staff costs
        • 9. Fair value re-measurement of share subscription agreement and warrants granted to Gilead
        • 10. Other financial income/expenses
      • Notes 11-20
        • 11. Income taxes
        • 12. Income/loss (-) per share
        • 13. Intangible assets
        • 14. Property, plant and equipment
        • 15. Other non-current assets
        • 16. Research and development incentives receivables
        • 17. Trade and other receivables and other current assets
        • 18. Current financial investments
        • 19. Cash and cash equivalents
        • 20. Share capital
      • Notes 21-30
        • 21. Deferred tax
        • 22. Lease liabilities
        • 23. Trade and other liabilities
        • 24. Deferred income
        • 25. Discontinued operations
        • 26. Note to the cash flow statement
        • 27. Off-balance sheet arrangements
        • 28. Contingent assets and liabilities
        • 29. Share based payments
        • 30. Related parties
      • Notes 31-34
        • 31. Consolidated companies as of 31 December 2020
        • 32. Financial risk management
        • 33. Statutory auditor’s remuneration
        • 34. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor
  • Magazine
    • Commercial
    • Science
    • Patients
Downloads

Research & Development

  • Our pipeline and drug discovery engine
  • Versatile target discovery platform
  • Our inflammation franchise
    • Filgotinib in RA
    • Filgotinib in IBD
    • Other indications with filgotinib
    • Our Toledo program
    • Our TYK2 program with GLPG3667
    • Our JAK1/TYK2 program with GLPG3121
    • Inlicensing to further strengthen the inflammation franchise
    • GLPG1972 in OA
  • Our fibrosis portfolio
    • About IPF
    • Our IPF trials
    • Our fibrosis collaborations
  • Other pipeline

You are here:

  • Home
  • R&DOur inflammation franchise
  • Our JAK1/TYK2 program with GLPG3121

Our JAK1/TYK2 program with GLPG3121

Our inflammation franchise
 CSR report
Galapagos NV • Annual Report 2020

We discovered GLPG3121 as a selective JAK1/TYK2 inhibitor. This asset is currently undergoing Phase 1 studies and preclinical data point to potential application of GLPG3121 in inflammatory diseases.

  • Downloads
  • Financial calendar
  • Glossary of terms
previous pagenext page

Magazine Looking ahead

Three inspiring inside stories that define the next chapter of Galapagos.

A landmark year for our commercial colleagues Improved opportunities in a larger haystack Embarking an era of patient partnership

Galapagos Annual Report 2020 (PDF)

(PDF:) Download PDF (4.8 MB)
English | Dutch
  • © Copyright 2021 Galapagos NV
  • Colophon
  • Contact
  • Privacy notice
  • Downloads
  • Glossary of terms

© Copyright 2021 Galapagos NV

nexxar - digital reporting evolved - Online Report